STUTTGART, Germany I June 28, 2025 I Vectorized antibodies obtained by in vivo expression of DNA or RNA are an emerging drug modality with potential to overcome several of the limitations of passive immunotherapy with antibodies produced ex vivo. La Merie Publishing released a new report about gene therapy technologies for in vivo expression of antibodies. The report “Vectorized antibodies by in vivo expression of DNA or RNA: a competitive business, stakeholder, technology and pipeline analysis from an industry perspective” analyzes stakeholders, R&D pipeline, profile & composition of drug candidates and business deals from an industry perspective as of June 2025.

Despite the clinical success of therapeutic antibodies, they still have several limitations including the high cost, caused by in great part by manufacturing and control. Development of the manufacturing process as well as commercial scale GMP manufacturing of antibodies in great amounts is complex process. Other limitiations refer to the inconvenience of frequent administrations associated with a unsatisfactory pharmacokinetic profile, challenging administration procedures to the eye (e.g. subretinal injection) or the central nervous system (e.g. intrathecal infusion with indwelling catheter) or side effects and limited efficacy upon systemic administration without tissue specificity.

In vivo expression of therapeutics antibodies by DNA or RNA may overcome some of the limitations of conventional antibody therapy. The antibody transgene may be delivered by viral vectors, by direct injection of plasmid DNA into the muscle followed by electroporation or by molecular formulations, such as lipid nanoparticles, for systemic administration.

Viral vectors are a validated delivery tool of DNA in gene therapy, but challenges remain in its clinical use, including the broad tropism and poor penetration of the blood brain barrier or the inner membrane line in the eye. Therefore, most of the companies developing vectorized antibodies by viral DNA have established technologies to engineer viral vectors for tissue specific tropism, wide-spread transduction of target cells, but de-targeting of unwanted tissues.

RNA for in vivo expression of antibodies needs a suitable carrier and delivery medium for administration. The development mRNA based COVID-19 vaccines has set up a standard method for in vivo delivery of mRNA to express vaccine antigens which is also suitable for antibody transgenes. And they have validated lipid nanoparticles as delivery vehicle. Next generation technologies of RNA (self-amplifying, circular) and of delivery molecules (other nanoparticles) may further improve efficacy and safety of RNA for expression of antibodies.

The report brings you up-to-date with information about and analysis of:

• Stakeholders: companies with technologies in viral DNA, oncolytic virus DNA, non-viral DNA and RNA; service providers and biopharmaceutical partners;
• Coroporate profiles of stakeholders: technology, territory, year of foundation, employees, financial situation and highest R&D stage
• Partnerships of vectorized antibody technology companies and biopharmaceutical companies;
• Vectorized antibody technologies; viral DNA, oncolytic virus DNA, non-viral DNA (plasmid, molecular formulation, cellular delivery) and RNA;
• Compositions of vectorized antibody product candidates: DNA or RNA, delivery method and route of administration;
• Pipeline of vectorized antibodies: in ophthalmology, oncology, neurology, infectious disease and other therapeutic areas;
• Clinical experience in safety and efficacy with vectorized antibodies;
• Molecular, preclinical and clinical profile of vectorized antibodies;
• Competitor analysis.

 

Methodology

This report evaluates the industry landscape of vectorized antibodies in research and development. The report provides a comprehensive overview of the R&D and partnering activities of pharmaceutical and technology companies in the field of vectorized antibodies by in vivo expression of DNA or RNA. This report is based on the identification and description of corporate stakeholders including biopharmaceutical companies and biotechnology companies. All publicly available information is fully referenced, either with more than 190 scientific references (abstracts, posters, presentations, full paper) or hyperlinks leading to the source of information, such as press releases, corporate presentations, annual reports, SEC disclosures and homepage content.

The report Vectorized antibodies by in vivo expression of DNA or RNA: a competitive business, stakeholder, technology and pipeline analysis from an industry perspective can be acquired at La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/vectorized-antibodies-by-in-vivo-expression-of-dna-or-rna-a-competitive-business-stakeholder-technology-and-pipeline-analysis-from-an-industry-perspective/

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.

La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.

SOURCE: La Merie Publishing